Recent data has shown efficacy of mutant BRAF ATP-competitive RAF kinase inhibitors, such as encorafenib, in combination with cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) receptor, for the treatment of BRAF V600E mutated CRC [2]. Here, BRAF is linked to colorectal carcinoma.